Navigation Links
Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
Date:3/26/2013

CHARLOTTESVILLE, Virginia und CAMBRIDGE, Massachusetts, March 26, 2013 /PRNewswire/ --

DART Therapeutics Inc., ein innovatives Biotechnologie-Unternehmen neuester Art, das sich auf die Entwicklung von Therapien für die Duchenne-Muskeldystrophie (DMD) konzentriert, und Biovista, ein führender Anbieter für die systematische Neupositionierung von Medikamenten, gaben heute bekannt, dass sie eine Forschungskooperation eingegangen sind, um neuartige Kandidaten für die Neupositionierung von Medikamenten für DMD zu identifizieren und zu entwickeln, wobei die Biovista-Technologie "Clinical Outcome Search Space" (COSS) ™ genutzt werden soll. Gemäß der Vereinbarung wird Biovista neuartige Kandidaten für die Neupositionierung identifizieren und die Firma DART Therapeutics wird die Möglichkeit haben, eine bestimmte Anzahl für die weitere Entwicklung auszuwählen. Die Bedingungen der Vereinbarung umfassen eine Vorauszahlung und nachgeschaltete erfolgsabhängige Zahlungen.

"Die Neupositionierung von Medikamenten ist ein wichtiger Ansatz in unserer Gesamtstrategie zur möglichst effizienten Identifikation neuartiger Behandlungsmethoden für DMD", sagte Gene Williams , Chief Executive Officer von DART Therapeutics. "Biovista und die COSS-Technologie sind führend in der systematischen Neupositionierung und gewährleisten uns die breitestmögliche Abdeckung aller Möglichkeiten der Neupositionierung, die wirklich starke Auswirkungen auf Patienten und ihre Familien haben können, die auf eine Behandlung für DMD warten."

"Das Unternehmen DART Therapeutics steht für ein einzigartiges Modell, das den Entwicklungsarm einer großen Interessengruppe von Patienten darstellt. Die Führungsrolle des Unternehmens bei DMD ist eine ausgezeichnete Ergänzung zu unseren eigenen F
'/>"/>

SOURCE Biovista, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Array BioPharma Inc. (NASDAQ: ARRY ) today ... Novartis Pharma AG to acquire worldwide rights to encorafenib ... This agreement is conditional on the closing of transactions announced ... which are expected to close in the first half ...
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The laboratory ... that has witnessed a number of technological advancements due ... regulatory requirements, growing need to integrate healthcare systems, and ... ease challenges in system integration. Key players in the ...
(Date:1/22/2015)... 22, 2015 zFlo Motion , a ... announce an exciting product from a new partner. STT-Systems ... over the past 15 years, with offerings in the optical-motion ... 3D IMU system (inertial measurement unit), iSen, is opening eyes ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 43D Motion Capture Just Got Easy 2
... Four Clinical Stage Product Candidates Adds to Robust ... ... Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) and MacroChem Corporation (OTC ... agreement,providing for Access to acquire MacroChem through the issuance of 2.5,million ...
... (Nasdaq: ALXN ), today announced that the Company ... Tuesday, July 29, 2008, at,10:00 a.m. Eastern Time (ET), ... the second quarter ended June 30, 2008. Alexion,anticipates releasing ... 29, 2008., To participate in this conference call, ...
... Exchange between Physician Community and Leading Biotechnology and ... ... EMD Serono, Inc. announced,today that the company has adopted ... Interactions with Healthcare Professionals.,The revised voluntary Code, which builds on ...
Cached Biology Technology:Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp. 2Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp. 3Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp. 4EMD Serono to Adopt Revised and Strengthened PhRMA Code 2EMD Serono to Adopt Revised and Strengthened PhRMA Code 3EMD Serono to Adopt Revised and Strengthened PhRMA Code 4
(Date:1/22/2015)... 2015 /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry ... new website design. "When we launched FindBiometrics 12 ... Peter O,Neill , founder and CEO of FindBiometrics. "Now it,s ... from the key players on a very broad scale.  We ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... sectors including technology and tech stocks, releases video from the ... pickpocket and security consultant Apollo Robbins . ... about the Wocket™ biometric smart wallet, a product of NXT-ID, ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... State University researcher has demonstrated that a variety of environmental ... animal but the next three generations of its offspring. , ... the way genes turn on and offthe epigenetic effect studied ... on in the current issue of the online journal ...
... sizes. Scientists have discovered simple rules that control leaf shape during ... able to accurately emulate leaf growth from a bud. "A ... said lead author Samantha Fox from the John Innes Centre on ... bud, not flat with a pointed tip." By creating a ...
... On March 9, the New York Academy of Sciences ... of Established Regulatory Guidance." This full-day conference will explore ... challenges for follow-on versions of complex drugs. , On ... draft guidelines for implementing the Biologics Price Competition and ...
Cached Biology News:Effects of environmental toxicants reach down through generations 2First model of how buds grow into leaves 2Newly released FDA draft guidelines for biosimilar drugs to be discussed at conference 2
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Biology Products: